Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map

We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimated the relative risk (RR) and 95% CI. We also created an evidence map showing the plausible benefits or harms of each intervention and the certainty of the evidence.FindingsWe examined 232 meta-analyses evaluating ten classes of diabetes drugs. We identified six risk and 38 protective associations showing a high strength of evidence. Six associations increased the risk of cardiovascular disease, including glimepiride (stroke [RR 2·01; 95% CI 1·02–3·98]), rosiglitazone (myocardial infarction [1·28; 1·02–1·62] and heart failure [1·72, 1·31–2·27]), and pioglitazone (heart failure [1·40; 1·16–1·69]). 38 associations decreased the risk of cardiovascular disease, including glucagon-like peptide-1 receptor agonists as a class (major adverse cardiovascular eve...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research

Related Links:

RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Type 2 diabetes (T2D) is a metabolic disorder of insulin resistance — a reduced sensitivity to the action of insulin — which leads to high blood sugar, or hyperglycemia. Approximately 12% of American adults have T2D, and more than one-third of Americans have prediabetes, a precursor to T2D. This is a major public health concern, as T2D dramatically increases risk for heart disease, including heart attacks, atrial fibrillation, and heart failure. The development and progression of T2D is affected by many factors. Some, such as a person’s race/ethnicity, age, and gender cannot be modified. Others, including...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Diabetes Exercise and Fitness Healthy Eating Heart Health Source Type: blogs
ConclusionAmong patients with AF, OSA is an independent risk factor for MACNE and, more specifically, stroke/SE.Graphical Abstract
Source: American Heart Journal - Category: Cardiology Source Type: research
AimDescribe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.Methods and resultsKey background characteristics were evaluated in 5050 patients randomized in VICTORIA and categorized into three cohorts reflecting their index worsening HF event. Differences within the VICTORIA population were assessed and compared with PARADIGM ‐HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and COMMANDER HF (A Stu...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionsIn AF patients, there is underuse of GDT for non-AF comorbidities. The association between GDT use and outcomes was strongest in heart failure and obstructive sleep apnea patients where use of GDT was associated with lower mortality and less AF progression.
Source: American Heart Journal - Category: Cardiology Source Type: research
Fitbit or Apple Watch for running? Garmin or Misfit for swimming? Sleep Cycle or Sleep as Android for sleep tracking? What about measuring heart rate, blood pressure, or tracking how to cut out stress from your life? Dozens of gadgets on the healthcare wearable market promise you a healthier lifestyle, but it’s easy to go astray in the jungle of digital health gadgets. Let me show you my top choices when it comes to health wearables and trackers. Guidance in the health wearable universe By now, I have tested and used more than a hundred devices and gadgets that measure health parameters or vital signs. Thus,...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Health Sensors & Trackers Portable Diagnostics activity fitness fitness trackers Health 2.0 Healthcare Innovation meditation mental health Personalized medicine sleep sleep optimization sleep tracking stress technology wear Source Type: blogs
CONCLUSIONS: Cancer patients are vulnerable to comorbidity related to heart and cerebral disease. The influence of comorbidities on prognosis is noticeable and specific both for the type of cancer and comorbidities. PMID: 31562288 [PubMed - as supplied by publisher]
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
For decades, doctors have known that losing weight can significantly lower risk of heart disease and by extension, reduce the risk of dying from heart-related events such as stroke and heart attack. Studies have shown that both lifestyle changes including diet and exercise as well as medications and weight-loss surgery can improve heart disease risk factors such as obesity and diabetes, for example, but data supporting the benefits of any of these approaches in actually lowering rates of heart events such as heart attack and atrial fibrillation, or in reducing early deaths from heart disease, have been less robust. The dat...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized diabetes Heart Disease Source Type: news
Abstract BACKGROUND: Poland is a country of high cardiovascular risk. Because depression was found to be a predictor of coronary artery disease and the prevalence of depressive symptoms (DSs) has risen worldwide, their monitoring in the population is desirable. AIM: We sought to evaluate the prevalence of DSs in relation to the socio-demographic status and selected types of cardio-vascular diseases in the adult Polish population. METHODS: A country-representative random sample of 2413 subjects, aged 18 to 79 years, was examined in 2011. Rates of self-reported cardiovascular conditions including hypertens...
Source: Kardiologia Polska - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research
More News: Actos | Atrial Fibrillation | Avandia | Byetta | Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Databases & Libraries | Diabetes | Empagliflozin | Endocrinology | Forxiga | Glimepiride | Heart | Heart Attack | Heart Failure | Invokana | Jardiance | Sodium | Stroke | Victoza